Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2010

View Archived Issues

Roche presents novel DP2 receptor antagonists

Boehringer Ingelheim presents novel 11-beta-HSD1 inhibitors

Takeda claims novel H+/K+-ATPase proton pump inhibitors

Boehringer Ingelheim claims new Mnk1 and/or Mnk2 inhibitors

Takeda identifies novel Polo-like kinase inhibitors

Vorinostat exhibits safety and tolerability in phase II trial in advanced renal cell carcinoma

Clinical phase I/II data on TAK-700 in metastatic CRPC disclosed

Chugai seeks Japanese approval for Herceptin in combination with Xeloda for gastric cancer

Cilengitide does not exhibit antitumor activity in phase II nonmetastatic CRPC trial

Paclitaxel nanoparticles potent as second-line therapy in phase II trial in metastatic UC

Tripep changes name to ChronTech Pharma

A.P. Pharma receives FDA complete response letter for APF-530

Cytokinetics opens phase IIa CK-2017357 trial in ALS

GlaxoSmithKline begins phase III Relovair program in asthma

Synergy begins phase IIa trial of SP-304 in patients with constipation

Takeda withdraws MAA for prolonged-release Competact for type 2 diabetes

PPD and Southern Research Institute collaborate on flu vaccine research services

OSI receives positive opinion on Tarceva for NSCLC from European health authorities

Agennix raises funds for continued talactoferrin development

AstraZeneca and Torrent Pharmaceuticals enter into branded generics agreement / News in Context

Helix BioPharma nears completion phase II trial of topical interferon alpha-2b for anogenital warts

Novel mu opioid receptor inverse agonist in phase I development by GSK for obesity

Roche submits MAA with EMA to extend MabThera label

FDA issues warning for highest approved dose of cholesterol-lowering Zocor

European orphan drug designation for Allon Therapeutics' davunetide in PSP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026